Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in March 2010, to inform of new safety information and advice.
| Date issued | Product | Safety information |
|---|---|---|
| 12 March 2010 | Regranex (becaplermin) (2766Kb) |
Contraindicated in patients with malignancies |
| 12 March 2010 | Aclasta (zoledronic acid) (2781Kb) |
Reports of renal impairment and renal failure |
| 22 March 2010 | Fungizone (parenteral amphotericin B) (58Kb) |
Risk of potentially fatal overdose due to confusion between lipid-based and non-lipid-based formulations |
| 22 March 2010 | Faslodex (fulvestrant) (27Kb) |
New recommended dosing regimen |
| 25 March 2010 | Rifadin for infusion 600 mg (rifampicin) (41Kb) |
Product has been reformulated and must now only be diluted with 5% dextrose or normal saline |
